Login to Your Account



Clinic Roundup


Wednesday, June 12, 2013
• Medicago Inc., of Quebec City, said Health Canada cleared the firm to start a Phase II dose-sparing trial for its H5N1 avian influenza VLP vaccine candidate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription